Results 311 to 320 of about 103,481 (331)

Treatment of Acromegaly with Dopamine Agonists

Endocrinology and Metabolism Clinics of North America, 1992
This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical ...
Craig A. Jaffe, Ariel L. Barkan
openaire   +3 more sources

Dopamine: Agonists and Neurodegenerative Disorders

Current Drug Targets, 2018
Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias.
Yasir Hasan Siddique, Saba Khanam
openaire   +3 more sources

Clinical Pharmacology of Dopamine Agonists

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
With the availability of newer dopamine agonists selective for dopamine (D2) receptor subtypes, medical management of Parkinson's disease has progressed substantially. These agents can decrease the frequency of ergot‐related side effects and dyskinesias.
openaire   +3 more sources

Dopamine agonists and therapy compliance

Neurological Sciences, 2008
Dopamine replacement therapy in Parkinson's disease improves motor symptoms, however some patients suffer from motor and behavioural disturbances attributable to taking doses of medication well beyond the dose required to treat their motor disabilities.
openaire   +3 more sources

Prolactinomas and Resistance to Dopamine Agonists

Hormone Research, 1992
Among 288 patients with prolactinoma (aged 12-62 years; 242 women), 27 were diagnosed as resistant to bromocriptine as their plasma prolactin (PRL) levels remained elevated despite long-term (3 months or more) treatment at high doses (> or = 15 mg daily).
Thierry Brue, I. Morange, I. Pellegrini, A. Priou, P. Jaquet   +4 more
openaire   +3 more sources

Vascular Dopamine and Dopamine Receptor Agonists

1984
Regulation and modulation of the sympathetic nervous system have been and remain cornerstone strategies for the treatment of cardiovascular disease. Whereas stimulating, mimicking or antagonizing norepinephrine and epinphrine have been the most frequently utilized approach to cardiovascular renal therapeutics, the possibility that dopamine and dopamine
Robert W. Erickson, Eliot H. Ohlstein, Barry A. Berkowitz, Bodgan Zabko-Potavpovich   +3 more
openaire   +2 more sources

Dopamine agonist action of phencyclidine

Synapse, 2005
AbstractAlthough the psychotomimetic action of phencyclidine is often used to model a hypoglutamate theory of psychosis or schizophrenia, work also exists showing that phencyclidine has a significant affinity for the dopamine D2 receptor. The present study was done to determine whether phencyclidine has a direct functional dopamine‐like action on cells.
Mercedes Lasaga, Philip Seeman
openaire   +3 more sources

Dopamine agonist–resistant prolactinomas

Journal of Neurosurgery, 2011
The authors' object in this paper was to review the definition, epidemiology, biology, resistance mechanisms, and treatment options for dopamine agonist–resistant prolactinomas (DARPs). Prolactinomas are relatively unique among primary brain tumors in that medical treatment alone using dopamine agonists carries a high probability of disease control or ...
Michael C. Oh, Manish K. Aghi
openaire   +3 more sources

Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists

Journal of Neural Transmission, 1989
The dopamine (DA) D2 agonist bromocriptine produced dose-dependent locomotor depression in mice with intact stores of DA, as measured in automated activity cages. The DA D1 agonist CY208-243, reversed the bromocriptine-induced depression. Using direct observational analysis, another selective DA D2 agonist, quinpirole, induced dose-dependent depression
David M. Jackson, S.B. Ross, S. R. Edwards   +2 more
openaire   +3 more sources

Partial dopamine agonists in schizophrenia

British Journal of Hospital Medicine, 2005
The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify®) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play ...
openaire   +3 more sources